Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To enroll a large percentage of the cancer high-risk group and to simultaneously screen for various kinds of cancer, a modified combination assay of tumor markers and risk factors in serum was devised. A pilot study using 5 tumor markers, AFP, CEA, CA19-9, CA125, Dupan-2, as well as 3 risk factors of pepsinogen, PGI, PGII, PGI/II, showed 87.0% sensitivity and 58.8% specificity in 54 patients with various cancers and 163 healthy subjects. Eighty percent of stage I or II cases were detected except for one stage I case of right lung cancer and one stage II case of oral cavity cancer. Field work is now under way to detect various cancers among approximately 1000 inhabitants above 50 years of age in a particular town using 11 tumor markers and 3 risk factors. One hundred fifty three of 967 cases (male 372, female 595) showed various abnormal values and some were examined further as higher risk cases to detect particular cancers suspected from the results of the modified combination assay. At present, 5 PAP positive cases were referred to urological clinic for examination and 3 were confirmed histologically as prostatic cancer. This corresponds to approximately a 0.8% of detection rate which is more than 40 times the prostatic cancer mortality. Other kinds of cancer are still under investigation at various specified clinics. If cancer is not detected in these higher risk cases, they will be followed year to year. Further, the most suspicious cases will be examined at a chromosome or DNA level.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Clinical preventive medicine in cancer diagnosis--proposal for a new cancer diagnostic system in an aging society]. 836 Oct 26

Macrophage colony-stimulating factor (MCSF) was used in the treatment of pancytopenia for a 64-year old man with prostatic cancer with bone metastases. Pancytopenia was improved and tumor markers (PA, PAP, gamma-Sm) were normalized rapidly after castration. The alkali phosphatase (A1P) concentration decreased to the normal range and bone metastases were improved markedly after two courses of chemotherapy. To determine the clinical efficacy of M-CSF against tumor markers and A1P, we used M-CSF on two other patients with prostatic cancer with bone metastases. In one of them, the levels of the tumor markers decreased from the initiation of the injection of M-CSF, but gradually increased to the initial levels after the last injection. The total A1P concentration was not changed by M-CSF, but the A1P-3 concentration decreased and continued to decline. These findings suggest that M-CSF has an antitumor effect and that it can be effective in the treatment of prostatic cancer with bone metastases.
 ...
PMID:[Macrophage colony-stimulating factor for treatment of prostatic cancer with bone metastases]. 846 May 79

Cell kinetics were measured in vivo in four experimental rat prostatic adenocarcinomas grown in normal or castrated rats. The aim was to investigate the effect of castration on growth rate and cell kinetics in hormone sensitive and hormone insensitive prostatic carcinomas. We used two anaplastic, hormone insensitive, fast growing tumors (Dunning R-3327-AT1 H and E), as well as two well differentiated, hormone sensitive, slow growing tumors (R-3327-H and R-3327-PAP). DNA ploidy, S-phase transit time (Ts), the labeling index (LI) and potential doubling time (Tpot) was determined by dual parameter flow cytometry, after in-vivo labeling, using bromodeoxyuridine (BUdR) and the tumor doubling time (DT) was determined from growth curves. After castration DT in the hormone sensitive H-subline changed from 21.7 days to 82.0 days, and in the PAP-subline from 22.2 days to 33.2 days. No significant changes in Tpot were observed. In the anaplastic tumors no differences in neither DT nor Tpot were seen. The cell loss factor (CLF) was relatively low in the two anaplastic tumors (0.55-0.59) compared to the well differentiated tumors. The CLF was unaffected by castration in the poorly differentiated tumors, whereas it increased significantly (from 0.75 to 0.92, P = 0.005) after castration in the H-tumor, and showed a non-significant increase in the PAP-tumor. This implies that the decrease in tumor growth in the hormone sensitive tumors is due to an increase in cell death, not a decrease in cell proliferation. These data indicate that CLF is the dominating factor in the reduced growth following androgen ablation in an androgen sensitive tumor. This study suggests that Tpot might be an additional predictor of a tumors proliferating rate and it may provide important information of the human prostatic cancer.
 ...
PMID:The effect of castration on tumor growth rate and cell kinetics in hormone sensitive and hormone insensitive rat prostatic adenocarcinomas. 857 60

To determine whether long-term oral administration of UFT, a combination of 5-fluorouracil and uracil, in addition to conventional estrogen therapy improved the response and survival of the patients with advanced stage D2 prostate adenocarcinoma, a randomized prospective study was performed with either estrogen alone (Honvan 200 mg/day or presexol 1 mg/day: group A) or estrogen plus UFT (400 mg/day:group B). This study comprises 34 newly diagnosed patients with poorly differentiated prostatic adenocarcinoma (18 patients in group A and 16 in group B). Survival from all causes of death or cancer-specific death were compared using Kaplan-Meier actual methods among the patients separated by histological composition of tumors analyzed WHO histologic patterns, score of extent of disease (EOD), and with or without normalization of serum PSA or PAP levels after treatment. Although combination therapy with UFT against overall survival was effective without statistical significance, better survival in this group than the patients treatment with estrogen alone assessed among the patients whose tumor contained more than 70% of medullary and/or column-cord histological components. The survivals among the patients with EOD score 3 and whose serum PSA or PAP levels did not lead to decrease within normal levels after treatment were also better in group B than in group A. These findings suggest the validity of the combination therapy with UFT in addition to estrogen against highly advanced prostatic cancer patients whose tumor composed of abundant non-hormone-refractor histological components.
 ...
PMID:[Combination therapy with estrogen and UFT in newly diagnosed prostatic cancer (poorly differentiated, stage D2)]. 861 89

Eighteen previously untreated patients with metastatic carcinoma of the prostate were treated with LHRH analogue. They were divided into 3 groups according to the degree of glandular differentiation. In all groups, a transient rise of PAP and PSA was observed after the LH and testosterone surge. However, relative values of LH, testosterone, PAP and PSA did not differ significantly among the 3 groups. These facts suggest that a transient rise of PAP and PSA is caused by testosterone surge independently from the degree of glandular differentiation after LHRH analogue administration in patients with advanced prostatic cancer.
 ...
PMID:Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation. 872 45

Malignant pleural effusions due to prostatic carcinoma are rare. We examined the cytologic and clinical presentations of 14 malignant pleural effusions caused by prostate cancer. These cases represented 2.3% of all positive pleural effusions at our institution. All patients (n = 10) had high grade, high stage tumors, including three with small cell anaplastic carcinoma. Three cases had clinically documented metastases to pleura, and in two cases, metastases were documented at autopsy. Most tumor cells had large nucleoli and were arranged in small, loosely cohesive groups. Fluids due to the small cell type of prostate carcinoma often contained a mixture of cells similar to those seen in small cell carcinoma of other sites such as the lung, as well as cells resembling the more typical type of prostate cancer. Prostatic specific antigen and prostatic acid phosphatase were positive in less than 50% of these malignant effusions. We conclude that prostatic carcinoma in pleural effusions occurs most commonly in high grade, high stage tumors and has a characteristic cytologic appearance. Negative staining for PSA and PAP does not rule out a prostatic source for malignant cells in effusions.
 ...
PMID:Cytology of metastatic adenocarcinoma of the prostate in pleural effusions. 887 30

In the normal prostate, transforming growth factor-beta 1 (TGF-beta 1) inhibits epithelial cell growth and is associated with apoptosis. The role of TGF-beta 1 in prostate cancer remains, however, unclear. In this work, the expression of TGF-beta receptor type I and II (TGF beta-RI and TGF beta-RII) in the Dunning R3327 PAP adenocarcinoma was studied, after castration and oestrogen treatment. Since castration induces apoptosis in the rat ventral prostate (VP) [21], but not in the Dunning R3327 PAP tumour [46], the TGF-beta receptor levels in the tumour were compared to the receptor levels in the VP. Methods used were competitive reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry. In the VP, TGF beta-RI and TGF beta-RII expressions were increased after castration, indicating a negative regulation of TGF beta receptors by androgens. In the Dunning tumour, TGF beta-RI and TGF beta-RII levels were elevated and only TGF beta-RI showed a clear-cut increase after castration. The receptors were located in epithelial and smooth muscle cells in the VP and mainly in epithelial cells in the Dunning tumour. In conclusion, the elevated TGF beta receptor levels and the diminished androgen regulation of TGF beta-RII in the tumour distinguish the Dunning R3327 PAP tumour from the normal prostate and need to be further elucidated.
 ...
PMID:Expression of transforming growth factor-beta receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment. 914 76

Procollagen 1 carboxyterminal peptide (P1CP) is thought to be an indicator of new bone formation. The present report demonstrates that effective endocrine therapy induced an initial increase followed by a delayed decrease in serum levels of P1CP and alkaline phosphatase in spite of an immediate decrease in serum PSA and PAP and improvement of clinical symptoms in prostate cancer patients with bone metastases. The transient increase in P1CP and alkaline phosphatase is a healing reaction and is followed by apparent improvement. Short-term effects of endocrine therapy on prostate cancer patients with bone metastases should be comprehensively evaluated based upon the entire spectrum of clinical and laboratory findings including serial changes of serum prostate markers and bone markers as well.
 ...
PMID:A transient increase in serum procollagen 1 carboxyterminal peptide following effective treatment in prostate cancer patients with bone metastases. 925 25

With the purpose of establishing morphogenetic features of precancer and early cancer of the prostate gland a comparative immunomorphological evaluation was done of the prostate tumor markers (PAP, PSA, PCNA, and 34 beta E12). Due emphasis is given to the part the basal cell dysplasia plays in morphogenesis of prostatic cancer. The precancer lesions of the prostate include atypical adenomatous hyperplasia, grade I and II prostatic intraepithelial neoplasia (PIN). Grade III prostatic intraepithelial neoplasm is cancer in situ, or uninfiltrative (unpalpable) cancer of the prostate. PIN patients are at high risk for subsequent development of invasive prostatic carcinoma.
 ...
PMID:[The morphogenesis of cancer of the prostate (immunohistochemical research)]. 969 75

Prostate carcinoma occurs infrequently in patient less than 50 years old with an incidence of 0.8% to 1.1%. In literature are described less than 20 cases occurred in younger men (< 40 years old). A 36 year-old man with a two-months history of lower back pain, anorexia and loss of weight, showed at clinical examination a mild enlargement of inguinal lymph nodes and right inferior leg and scrotus edema. CT scan demonstrated marked enlargement and fusion of pelvic, inguinal, sacral and periaortic nodes with a pelvic mass that caused local ureterohydronephrosis and obstruction of the urinary flow. X-rays showed osteoblastic metastases. At total body scintigram were observed fixation areas corresponding to lumbar metamers, pelvis, thigh bones, left humeral head, left acromioclavicular articulation and multiple ribs. Tumor markers resulted negative except prostate specific antigen (PSA: 500 mgr/ml) and prostatic acid phosphatase (PAP: 208 U/l); prostate biopsy showed an undifferentiated carcinoma. The patient was submitted to right percutaneous nephrostomy, chemotherapy (PEB, cisplatinum, etoposide and bleomycin for 6 cycles) and ormonotherapy (LHRH analogues) reporting a clinical partial response. After 6 months the disease progressed and was started a second line chemotherapy. After 18 months from diagnosis patient is still alive with progressing disease. Our patient represents, with respect to many features, an original clinical case of prostate carcinoma occurring in young age, for the atypical association of an undifferentiated carcinoma with high levels of PSA and PAP and with osteoblastic-pattern of bone metastases. Further studies would be useful to identify new risk factors for development of prostate cancer in young men in order to achieve early diagnosis.
 ...
PMID:Atypical case of metastatic undifferentiated prostate carcinoma in a 36 years old man: clinical report and literature review. 1114 22


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>